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Transcriptomics of Gabra4 knockout mice
reveals common NMDAR pathways
underlying autism, memory, and epilepsy
Cuixia Fan1,2†, Yue Gao1,3,4†, Guanmei Liang1,3,4, Lang Huang3,5, Jing Wang1, Xiaoxue Yang1, Yiwu Shi2,
Ursula C. Dräger6, Mei Zhong1, Tian-Ming Gao3,5 and Xinping Yang1,3,4*
Abstract
Autism spectrum disorder (ASD) is a neuronal developmental disorder with impaired social interaction and
communication, often with abnormal intelligence and comorbidity with epilepsy. Disturbances in synaptic
transmission, including the GABAergic, glutamatergic, and serotonergic systems, are known to be involved in the
pathogenesis of this disorder, yet we do not know if there is a common molecular mechanism. As mutations in the
GABAergic receptor subunit gene GABRA4 are reported in patients with ASD, we eliminated the Gabra4 gene in
mice and found that the Gabra4 knockout mice showed autistic-like behavior, enhanced spatial memory, and
attenuated susceptibility to pentylenetetrazol-induced seizures, a constellation of symptoms resembling human
high-functioning autism. To search for potential molecular pathways involved in these phenotypes, we performed a
hippocampal transcriptome profiling, constructed a hippocampal interactome network, and revealed an upregulation
of the NMDAR system at the center of the converged pathways underlying high-functioning autism-like and anti-
epilepsy phenotypes.
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Introduction
Autism spectrum disorder (ASD) is a group of neurodeve-
lopmental disorders with core clinical features of impaired
social interaction, and communication withdrawal, stereo-
typed behaviors, and restricted interests [1, 2]. Individuals
with autism show a wide range of variations in intelligence
quotient (IQ); it can be normal, above average, or with in-
tellectual disability. About 55% show intellectual disability
(IQ < 70) [3] and 30% of children with autism may have
severe intellectual disability [4]. ASD without an intellec-
tual disability is called high-functioning autism (HF-ASD)
[4]. About 20–30% of autistic children show symptoms of
epilepsy [5, 6], whereas HF-ASD individuals have a lower
incidence of epilepsy [7, 8]. These reports suggest
that there might be an underlying relationship between
autism, intelligence quotient, and epilepsy.
ASD shows high genetic heterogeneity. Targeted stud-
ies have identified several synaptic cell adhesion mole-
cules such as neuroligins (NLGN3, NLGN4) [9],
neurexins (NRXN1 [10], CNTNAP2 [11]), scaffolding
proteins SHANK2 [12] and SHANK3 [13], and other
molecules in synaptic transmission [14–16]. Genome
scale genotyping technologies, such as microarray-based
comparative genomic hybridization (CGH) and whole
exome sequencing (WES), have detected a large number
of genomic copy number variations (CNVs) [17], point
mutations, and small insertion/deletions [18–20].
A general explanation for the high genetic heterogen-
eity despite similar phenotypic features is the hypothesis
that the risk genes share a common molecular network
[19, 21]. Together with our collaborators, we searched
for common molecular mechanism by constructing a
protein-protein interaction network for autism from 191
autism candidate genes by screening the whole human
orfeome in 2014 [22]. Since then, the autism candidate
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genes have been increased dramatically because of
genome-scale search for disease-associated genes. There
are thousands of candidate genes now, yet we still do
not know the common molecular mechanism. There-
fore, it is imperative to identify the convergent pathways
for this highly heterogenic disease. Recent transcriptome
studies reveal quantitative differences in gene expression
levels in postmortem brain tissues from autistic patients
[23, 24], and identify some enriched pathways [25]. The
transcriptomic analyses of brain tissues can provide in-
sights into convergent molecular pathways in shared be-
havioral outcomes [25]. Due to the limitation of the
availability of postmortem brain tissues from autism pa-
tients, different genetic mouse models for autism are es-
sential for such studies.
As described above, some genetic variants in genes en-
coding for synaptic proteins [14–16, 26] are found to be
causal to autism, pointing to the neurotransmission dys-
function as a potential underlying mechanism. The most
common neurotransmitter systems involved in the
pathogenesis of ASD are the GABAergic, glutamatergic,
and serotonergic systems [27, 28], yet we do not know
their connections at molecular level. We thought that,
by knocking out the disease candidate genes in these
three systems and looking for dysregulated pathways, we
might be able to find the converged pathways linking
these three neurotransmission systems to the different
phenotypic domains of autism.
Dysfunction of GABAergic signaling in early embryo
development can lead to autism [29]. γ-Aminobutyric
acid (GABA) receptors were also reported to be down-
regulated in postmortem autistic brain samples [30]. As-
sociation studies also suggest that GABRA4 and
GABRB1 contribute to the susceptibility for autism [31].
A family-based association and linkage disequilibrium
study has found a genetic interaction between GABRA4
and GABRB1 in the etiology of autism [32]. Variations
of GABRA4 were found in ASD patients [32, 33]. The
GABRA4 is mainly expressed in the thalamus, striatum,
cerebral cortex, dentate gyrus (DG), and CA1 region of
hippocampus [34].
GABRA4 is an essential subunit for extrasynaptic
GABA receptor α4βδ GABA(A) receptors. Chandra
et al. generated the first Gabra4 knockout mouse model
which exhibits a lack of tonic inhibition in DG cells and
thalamic relay neurons, and is insensitive to the sedative
and analgesic effects of an extrasynaptic GABA receptor
agonist gaboxadol [34]. Three other studies show that
Gabra4 knockout mice restores synaptic plasticity and
spatial learning during puberty [35], and the mice exhibit
enhanced trace and contextual fear conditioning [36],
and have larger dendritic spine and shaft profiles [37].
The GABAergic miniature inhibitory postsynaptic cur-
rents (mIPSCs) were reported to be decreased [34], while
NMDA/AMPA conductance ratio [38] was reported to
be increased. However, these previous Gabra4 knockout
mice were not evaluated for the autistic phenotypes, in-
cluding the core features of autism such as impaired so-
cial interaction, stereotyped behaviors, or restricted
interests. Here, in order to establish mutant GABRA4 as
a causal gene in autism and search for underlying mech-
anisms, we generated Gabra4 knockout mice
(Gabra4−/−) which showed core features of autism, en-
hanced spatial memory, and attenuated susceptibility to
pentylenetetrazol-induced seizures. These phenotypes
turn out to be similar to those of high-functioning aut-
ism. To search for the converging pathways underlying
these phenotypes, we then performed hippocampal tran-
scriptomics and interactomics studies and revealed a
central position of the N-methyl-D-aspartate receptors
(NMDARs) in the interconnected pathways linking aut-
ism, learning/memory, and epilepsy.
Materials and methods
Animal
The mice were housed under standard conditions (12 h/
12 h light/dark cycle, access to dry food and water ad
libitum). All the experimental procedures involving mice
were approved by the Committee on Animal Care and
Use at the Southern Medical University.
Generation of Gabra4 knockout mice
The generation of Gabra4 knockout C57BL/6 mice by
transcription activator-like (TAL) effector nucleases
(TALEN) technology [39] was carried out in Cyagen Bio-
sciences Inc. (China). Briefly, exon 1 of mouse Gabra4
gene (GenBank accession number, NM_010251.2) was
selected as target site, and TALEN mRNAs generated by
in vitro transcription were then injected into fertilized
eggs for KO mouse productions (Additional file 1: Figure
S1A). The products were Sanger-sequenced to confirm
the deletion. The details were provided in Supporting
Information.
Behavior analysis
All the tested subjects were 6–8-week-old male mice.
Data were expressed as means ± SEM values and were
assessed two-way analysis of variance (ANOVA) (Morris
water maze test), unpaired two-tailed t test (three-cham-
ber test, self-grooming test, marble buried test, open
field test, elevated plus test, fear conditioning test, Y
maze test, Morris water maze test) for comparisons
using GraphPad Prism version 6 Software.
Seizure susceptibility test
Pentylenetetrazol (PTZ, SIGMA) was dissolved in 0.9%
saline and administered intraperitoneally to the wild-
type and Gabra4−/− mice (5–6-week-old males) at a dose
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of 60 mg/kg body weight in a total volume of 0.20–0.25
ml. The mice were monitored and video-recorded in a
clear cage for 30 min. The video recordings were used to
confirm the visual range of seizures. The behavioral indi-
cators of seizure activity were as follows: (I) the first
myoclonic twitch, (II) clonic convulsions for at least 5 s,
(III) tonic hindlimb extension, and (IV) death [40].
RNA preparation
For each genotype, three RNA samples were prepared.
Each RNA sample was extracted from dissected hippo-
campi of three adult mice according to the manufac-
turer’s protocol (RNAeasy Mini Kit, Qiagen, USA). The
quality and yield of the isolated RNAs was assessed
using a NanoDrop Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA, USA) and Agilent 2100 Bioa-
nalyzer (Agilent Technologies, Santa Clara, CA, USA).
Only RNAs with a high RNA integrity number (RIN > 9)
were selected and used for the subsequent sequencing.
RNA-seq and differential expression analysis
RNA sequencing was performed at Berry Genomics
(Beijing, China) using Illumina NovaSeq. Reference gen-
ome (mm10) and gene model annotation files were
downloaded from UCSC Genome Browser. Reads num-
bers mapped to each gene were counted using HTseq-
count (v0.9.0). Raw counts of genes with > 1 counts in at
least four samples were used for the principle compo-
nents analysis (PCA) by plotPCA DEseq2 function. Dif-
ferential expression analysis on two groups was
performed using the DESeq2 (v1.20.0) and the edgeR
(v3.22.5). Differentially expressed genes (DEGs) were de-
termined using a cutoff of adjusted p < 0.05 for DESeq2
and p < 0.01 for edgeR. Log2-transformed differential
expressed genes data were used for expression heatmap
by pheatmap1.0.10 package.
Quantitative real-time PCR
Total mRNAs from hippocampal tissues were extracted
using standard column purification according to the
manufacturer’s instructions (RNAeasy Mini Kit, Qiagen,
USA), and reverse transcription of RNAs into cDNA
was performed using Evo M-MLV RT kit following the
manufacturer’s instructions (Accurate Biotechnology Co.
Ltd, China). Real-time PCRs were performed using
Roche LightCycle 480II and SYBRR Green Realtime
Master Mix (TOYOBO, Japan) following manufacturer’s
instructions. All data were normalized to the expression
of Gapdh. The relative expression level was calculated
using the 2−ΔΔCT method. The primers for qPCR were
listed in Additional file 1.
Co-immunoprecipitation
The hippocampal tissue was harvested in lysis buffer
(Beyotime Biotechnology, China) with 1 mM PMSF. Tis-
sue lysate was incubated on ice for 15 min and the deb-
ris was removed by centrifugation at 14,000 g for 15 min
at 4 °C. A volume of 500 μl lysate was incubated with
primary antibody or IgG antibody at 4 °C overnight, and
20 μl of protein A/G plus-Agarose (Santa Cruz, USA)
was added into the mixture and then incubated on a ro-
tating device for 3 h at 4 °C. The immunoprecipitates
were collected by centrifugation at 1,000 g for 5 min at 4
°C. The pellets were washed with 500 μl of lysis buffer
(with 1 mM PMSF) for three times, boiled in protein
loading buffer for 5 min, and then run on 8-12% SDS-
PAGE gels and transferred to PVDF membrane (BioRad,
USA). The membrane was blocked with 5% skim milk in
TBST for 1 h at room temperature and incubated with
primary antibody at 4 °C overnight. The membrane was
washed three times (each time for 5 min) and then incu-
bated with second antibody for 1 h at room temperature.
Horseradish peroxidase (HRP) conjugated anti-IgG anti-
body was detected using Clarity Western ECL substrate
(Bio-Rad, USA) with FluorChem E system (ProteinSim-
ple, USA). The following primary antibodies were used:
rabbit anti-GRIN1, rabbit anti-GluN2B, rabbit anti-
PSEN1 (1:1,000, Cell Signaling Technology, USA). HRP-
conjugated goat anti-rabbit IgG antibody and normal
rabbit IgG antibody were purchased from Cell Signaling
Technology.
Functional analysis of differentially expressed genes
Functional annotations were done using Database for
Annotation, Visualization and Integrated Discovery (DA-
VID) tools (v6.8) and terms were identified with false
discovery rate (FDR) less than 0.05. Visualization and
plot of top selected terms were done using ggplot2 pack-
age (v3.0.0). Enrichments were also performed for candi-
date genes of ASD, epilepsy, and schizophrenia. More
details and data sources were provided in Supporting
Information.
Construction of hippocampal interactome, co-expression
network, and DEG interactome
We constructed a hippocampal interactome by mapping
15,254 expressed genes from the mouse hippocampal tran-
scriptome to the whole mouse interactome from Biological
General Repository for Interaction Datasets (BioGRID). We
calculated correlation coefficient using FPKM value (frag-
ments per kilobase of transcript per million mapped reads)
and constructed a co-expression network at a cutoff 0.75 of
correlation coefficient using weighted correlation network
analysis (WGCNA). We mapped the 1,247 DEGs to the
mouse hippocampal interactome to extract hippocampal
DEG interactome containing these DEGs and their first
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neighbors if they have both physical interaction and co-
expression relationship. For extraction of the networks, the
self-loop edges and zero-degree nodes were removed. In
order to control the extraction of the DEG-subnetwork
from the protein-protein interaction (PPI) network, we
shuffled the nodes of the PPI network for 1,000 times
followed by subnetwork extraction. Then the sizes of
control subnetworks were plotted in comparison with the
size of the real DEG subnetwork (Additional file 1: Figure
S6A-B).
Subnetworks for autism and epilepsy and learning/
memory
We mapped the ASD candidate genes to the mouse
hippocampal interactome to extract a subnetwork
containing these candidate genes and their first neigh-
bors if they have both physical interaction and co-
expression relationship. The same method was also
applied for extracting epilepsy (EP) and learning/
memory (LM) subnetwork using their candidate genes
as we described above. We performed the same net-
work randomization to control the extraction of these
subnetworks as described above. Then the sizes of
control subnetworks were plotted in comparison with
the sizes of the real ASD, LM, or EP subnetworks
(Additional file 1: Figure S6C-H).
Gene-pathway bipartite network analysis
The data of Kyoto Encyclopedia of Genes and Genomes
(KEGG) Orthology of mouse were downloaded from
KEGG database (https://www.genome.jp/kegg/pathway.
html) to construct a mouse gene-pathway bipartite net-
work. The hippocampal expressed genes of both wild-
type (WT) and Gabra4−/− mice were mapped to the net-
work and the hippocampal gene-pathway bipartite net-
work was extracted (Additional file 2: Table S17). The
DEGs, ASD candidate genes, EP candidate genes, and
LM-related genes (seed genes) were mapped to the
gene-pathway bipartite network, and the pathways that
were significantly enriched for seed genes (p < 10−6) and
contained at least ten seed genes were kept. The gene-
pathway bipartite subnetworks of DEGs, ASD candidate
genes, EP candidate genes, and LM-related genes were ob-
tained (Additional file 2: Table S18–21). The genes involved
in each pathway of these bipartite subnetworks were shown
in Additional file 2: Table S22–25 and NMDARs were
highlighted. A converged gene-pathway network module
shared by the ASD, EP, and LM gene-pathway bipartite
subnetworks was extracted (Additional file 2: Table S26).
The genes involved in each converged pathway were shown
in Additional file 2: Table S27, and NMDARs were
highlighted. The pathways enriched in DEG, ASD, EP, and
LM gene-pathway bipartite subnetworks were compared
with those enriched in corresponding PPI subnetworks
(Additional file 2: Table S28–31).
Electrophysiology
Mice 3–4 weeks old were used to electrophysiological
recording. Whole-cell patch-clamp recordings of hippo-
campus pyramidal neurons were carried out as previ-
ously described [41]. The detail procedure is provided in
Supporting Information.
Results
Gabra4 knockout mice exhibit autistic-like behaviors,
enhanced memory and attenuated susceptibility to
pentylenetetrazol
We generated Gabra4 knockout mice in the C57BL/6
strain by creating an 8-base deletion using TALEN tech-
nology. The genotypes of the mutant offspring were con-
firmed by Sanger sequencing of the PCR-amplified
target region on the genomic DNA extracted from
mouse pups (Additional file 1: Figure S1A).
We examined sociability and social novelty of the mu-
tant mice in a three-chambered apparatus. During ha-
bituation to the empty chambers, neither wild-type
(WT) nor Gabra4−/− mice showed any preference for ei-
ther left or right chamber (Additional file 1: Figure S1B).
After habituation, both WT and Gabra4−/− mice demon-
strated a clear preference for the social stimulus over an
empty cage, but WT mice showed better sociability
based on the sniffing time to the stranger than to the ob-
ject (Fig. 1a). But when a novel mouse was introduced
into the previously empty cage, the WT mice preferred
to sniff the novel mice, while the Gabra4−/− mice did
not show this preference (Fig. 1b), suggesting a deficit in
social-novelty seeking in the mutant mice. These results
demonstrated that the Gabra4−/− mice exhibited re-
duced social interaction tendencies, which are character-
istic features of autism. To exclude the possibility that
social deficits might have resulted from locomotor dys-
function, we evaluated locomotor performance in the
open field test and found that WT and Gabra4−/− mice
had no significant differences in the total distance trav-
eled (Additional file 1: Figure S1C). This result indicated
that both WT and Gabra4−/− mice have normal loco-
motor activity. In the open field test, we also measured
the center time during the first 5 min and found no
significant difference between WT and mutant mice
(Additional file 1: Figure S1D), suggesting that the mu-
tant mice had no anxiety. In addition, we also tested for
anxiety in the elevated plus maze and found no differ-
ences between the mutant and WT mice (Fig. 1c). We
performed self-grooming test and found that Gabra4−/−
mice displayed more frequent grooming compared to
WT mice (Fig. 1d), which is suggestive of stereotypical
autistic behaviors. However, in the marble burying test,
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the Gabra4−/− and WT mice buried approximately the
same number of marbles in a 30-min test (Additional file 1:
Figure S1E). Marble burying is commonly used to test for
repetitive, anxiety, and compulsive-like behaviors [42], but
the interpretation is controversial [43]. Considered together
with the results from elevated plus maze (EPM) (Fig. 1c)
and open field test (OFT) (Additional file 1: Figure S1D),
the result of marble burying can be interpreted as no anx-
iety in mutant mice.
We evaluated the cognitive function of the mutant
mice by performing Y-maze, fear conditioning, and Mor-
ris water maze tests. Compared to WT, the Gabra4−/−
mice showed a small but significant increase in their al-
ternation percentage during Y-maze testing (Fig. 1e),
suggesting that the mutant mice may have better spatial
learning and memory. We also conducted fear condi-
tioning test, and found that Gabra4−/− mice showed nor-
mal fear memory (Additional file 1: Figure S1F-G). We
further evaluated the spatial learning and memory ability
by Morris water maze, assessing learning capacity via es-
cape latency (i.e., time spent to reach the hidden plat-
form). During the training trials, the mice in all groups
showed significant improvement in escape latency time
to find the submerged platform, but the Gabra4−/− mice
were significantly faster than the WT mice (Fig. 1f), al-
though the swim velocity for the Gabra4−/− mice was
not significantly different compared with WT mice
(Additional file 1: Figure S1H). Gabra4−/− mice also had
higher number of crossing over the platform position
during reverse trials (Fig. 1g), confirming the enhanced
memory ability.
ASDs are frequently comorbid with epilepsy [5, 6] and
thus we tested the impact of the Gabra4 knockout on
susceptibility to the seizure-inducing drug pentylenetet-
razol (PTZ). At a dose of 60 mg/kg body weight, we
found that the percentages of PTZ-induced convulsions
and tonic were significantly decreased in the Gabra4−/−
mice compared to the control mice (Fig. 1h). Over 92%
(12/13) animals of WT mice exhibited at least one of all
three phases of seizures and 38.46% (5/13) died; but only
53.80% (7/13) of Gabra4−/− mice exhibited clonic and
tonic phases of seizure, and none died. This result dem-
onstrated that Gabra4 elimination attenuates the suscep-
tibility to PTZ-induced seizure.
We quantified the density of spines along 30 μm sec-
tions of dendrites in the hippocampus (Additional file 1:
Fig. 1 Autistic-like behaviors, enhanced learning/memory and attenuated susceptibility to pentylenetetrazol (PTZ) in Gabra4−/− mice. a Both WT
and Gabra4−/− mice showed significant preference for stranger mice over objects (***p < 0.0001, **p = 0.0147. n = 16 for WT, and n = 8 for
Gabra4−/− mice, Student’s t test). b WT mice showed significant preference to novel mice over familiar mice (*p = 0.0042. n = 16 for WT,
Student’s t test), but Gabra4−/− mice did not show such preference (ns, n = 8, Student’s t test). c Compared to WT mice, Gabra4−/− mice stayed
the same time in both closed and open arms during the 5-min elevated plus maze test (n = 9 for WT, and n = 8 for Gabra4−/− mice, ns no
significance, Student’s t test). d Gabra4−/− mice spent more time to self-grooming than WT (*p = 0.0326, n = 10 for WT, and n = 9 for Gabra4−/−
mice, Student’s t test). e Gabra4−/− mice showed increased spontaneous alternation during Y maze test (*p = 0.0187, n = 12 for WT, and n = 9 for
Gabra4−/− mice, Student’s t test). f Escape latency of Gabra4−/− mice in the Morris water maze (***p < 0.0001, n = 12 for WT mice, n = 16 for
Gabra4−/− mice. Two-way ANOVA test). g Number of platform crossings during probe trial in Morris water maze (**p = 0.0013, n = 12 for WT
mice, n = 16 for Gabra4−/− mice, Student’s t test). h Susceptibility to pentylenetetrazol in mice (In the test for 60 mg/kg PTZ, p = 0.0114, two-way
ANOVA test)
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Figure S2A). Gabra4−/− mice exhibited increased spine
density (p = 0.0403) (Additional file 1: Figure S2B). The
length and thickness of postsynaptic densities (PSDs)
did not show significant change (Additional file 1:
Figure S2D-E).
The hippocampal differentially-expressed genes are involved
in autism and epilepsy
To systemically explore the molecular mechanism under-
lying autism and anti-epilepsy phenotypes, we performed
transcriptome profiling on three mixed samples of hippo-
campal tissues from 12 adult Gabra4−/− mice (each sample
from four mice) and three mixed samples from 12 wild-
type controls (each sample from four mice). The samples
of Gabra4 knockout mice were well separated from those
of littermate WT mice in principle component analysis
(PCA), which demonstrated that the samples from WT
mice are good controls of the samples from the mutant
mice (Additional file 1: Figure S3A). We detected a total
number of 15,254 expressed genes (Additional file 2:
Table S1), of which 1247 were differentially expressed
genes (DEGs) (Additional file 2: Table S4), including 787
upregulated genes (Fig. 2a, Additional file 2: Table S5) and
460 downregulated genes (Fig. 2a, Additional file 2: Table
S6). The 787 upregulated genes show significant enrich-
ment with candidate genes for ASD (Fig. 2b), epilepsy
(Fig. 2c), and learning/memory (Fig. 2d), suggesting that
the upregulation of these genes may be involved in deter-
mining the autistic and anti-epilepsy phenotypes we ob-
served in the mouse model. The upregulated genes also
show significant enrichment with candidate genes of
schizophrenia (Additional file 1: Figure S4A). The down-
regulated genes, however, did not show enrichments with
the candidate genes for epilepsy, ASD, nor schizophrenia
(Fig. 2b, c, Additional file 1: Figure S4A).
We performed functional enrichment analysis on the
DEGs, and found that the upregulated genes and downreg-
ulated genes belong to distinct functional categories (Fig.
2e, f). The upregulated genes are enriched for functions in
neuronal development and neuronal connections, which
are shown in the enriched Gene Ontology (GO) terms
(Fig. 2e, Additional file 1: Figure S4B-C): (i) biological pro-
cesses such as axon development, synapse organization,
ion transport, and learning/memory (ii) cellular compo-
nents such as axon part, distal axon, synaptic membrane,
postsynaptic density, postsynaptic membrane, and presy-
napse; and (iii) molecular functions such as channel activ-
ity, metal ion transmembrane transporter activity, passive
transmembrane transporter activity, and substrate-specific
channel activity. Consistent with the enriched GO terms,
the upregulated genes are enriched in pathways regulating
neuronal development and synapse, such as cyclic adeno-
sine monophosphate (cAMP) signaling pathway [44], cal-
cium signaling pathway [45], and long-term potentiation
[46] and GABAergic synapse (Fig. 2f). The downregulated
genes are mainly enriched in the following GO terms (Fig.
2e, Additional file 1: Figure S4B-C): (i) negative regulation
of nervous system development and neurogenesis; (ii)
microtubule, proteinaceous extracellular matrix, extracellu-
lar matrix and extracellular matrix component; and (iii)
negative regulation of neurogenesis, acidic amino acid
transmembrane transporter activity, L-glutamate trans-
membrane transporter activity, and glycosaminoglycan
binding. Consistent with enriched GO terms, the downreg-
ulated genes are enriched in pathways regulating synapse,
such as focal adhesion [47], steroid biosynthesis [48], and
glutamatergic synapse (Fig. 2f).
We checked the relative expression level of the genes
involving inhibitory GABA and excitatory glutamate
transmissions, including GABA receptors and Glutamate
receptors (Additional file 1: Figure S3C-E). GABA A re-
ceptor alpha 2 (Gabra2) (Additional file 1: Figure S3C)
and glutamate receptor Grin1 was upregulated
(Additional file 1: Figure S3D), but Grin2c downregu-
lated (Additional file 1: Figure S3D). The expression
levels of Gabra2 and Grin1 were confirmed by qRT-
PCRs (Additional file 1: Figure S3F-G).
Differential subnetwork enriched for genes involved in
autism, epilepsy, and learning/memory
In order to search for a molecular network underlying
the autistic-like and anti-epilepsy phenotypes, we
first generated a mouse hippocampal interactome
(Additional file 1: Figure S5), which contains 4204
nodes and 9205 edges by integrating the hippocampal
expressed genes and protein interaction data from
BioGRID, and then extracted DEG subnetwork con-
taining these DEGs and their first neighbors if they
have both physical interaction and co-expression rela-
tionship (Fig. 3a). The DEG subnetwork contains 143
nodes and 145 edges (Additional file 2: Table S7). We
evaluated the involvement of the DEGs in the autistic
behaviors, anti-epilepsy phenotype, and enhanced
learning/memory by the enrichment analysis of the
related genes. Compared to all DEGs, the DEG sub-
network exhibited a notable additional enrichment
with both autism candidate genes (fraction of ASD
candidate genes = 0.2028 (29/143)) (Fig. 3b), epilepsy
candidate genes (fraction of epilepsy candidate genes
= 0.1608 (23/143)) (Fig. 3c), and genes related to
learning and memory (fraction of learning/memory
candidate genes = 0.1958 (78/143)) (Fig. 3d).
The DEG subnetwork is enriched in pathways that
are reported to be involved in autism and epilepsy,
such as long-term potentiation [46], the cAMP signal-
ing pathway [44], and mitogen-activated protein kin-
ase (MAPK) signaling pathway [49] (Fig. 3e). These
results suggest that the DEG subnetwork may contain
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Fig. 2 Hippocampal transcriptome sequencing analysis and functional annotation of differentially expressed genes. a Pie chart shows 787 up-
regulated genes and 460 downregulated in Gabra4 knockout mice (n = 3 samples per genotype). b–d Autism spectrum disorder (b), epilepsy (c),
and learning/memory (d) candidate genes are enriched in Gabra4−/− differential expression genes. ***p < 0.0001, Fisher’s exact test; Error bars
represent the standard error of the fraction, estimated using bootstrapping method with 100 resamplings. e, f The top enriched biological
processes of GO terms (e) and KEGG pathways (f) with upregulated genes and down-regulated genes. The enrichment analysis was performed
using DAVID bioinformatics tool with a p value cutoff of 0.05 and FDR less than 0.05
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pivotal pathways relevant for cognitive functions and
perturbation of the molecular network may lead to
autistic-like behaviors and neural synaptic activity re-
lated to epilepsy.
Hippocampal interactome subnetworks for autism,
epilepsy, and learning/memory
We mapped ASDs candidate genes on the mouse hippo-
campal interactome (Additional file 1: Figure S5) and
Fig. 3 Hippocampal DEG interactome enriched with candidate genes involved in ASD, epilepsy and learning/memory. a The protein interaction
network for DEGs (143 nodes and 145 edges). To extract the DEG subnetwork, a hippocampal interactome network was constructed by
integrating the 15,254 hippocampally expressed genes and a protein interaction data from BIOGRID, and then the 1,247 DEGs were mapped to
the hippocampal interactome to extract a subnetwork including DEGs and their first co-expressed neighbors. Red node: upregulated; blue node:
downregulated; gray node: without expression change; node with green border: co-expressed neighbor; gray line: protein-protein interaction
(PPI); double lines: PPI and co-expression. b Enrichment of ASD candidate genes in DEG subnetwork compared to all DEGs. Fraction of ASD
candidate genes = 0.0574 (876/15,254) in mouse expressed genes; 0.0874 (109/1247) in differentially expressed genes; 0.2028 (29/143) in DEGs in
the mouse hippocampal interactome. p = 7.8167E-06 between expressed genes and DEGs; p = 4.1585E-06 between expressed genes and DEGs in
the mouse hippocampal interactome; p = 2.0957E-09 between all DEGs and DEGs in the mouse hippocampal interactome. Error bars represent
the standard error of the fraction, estimated using a bootstrapping method with 100 resamplings. **p < 0.01; ***p < 0.001 two-tailed fisher-exact
test. c Enrichment of epilepsy candidate genes enriched in DEG subnetwork compared to all DEGs. Fraction of epilepsy candidate genes = 0.0325
(496/15,254) in expressed genes; 0.0609 (76/1247) in DEGs; 0.1608 (23/143) in DEGs in the mouse hippocampal interactome. p = 1.001E-07
between expressed genes and DEGs; p = 2.156E-10 between expressed genes and DEGs in the mouse hippocampal interactome; p = 3.7105E-06
between in all DEGs and DEGs in the mouse hippocampal interactome; Error bars represent the standard error of the fraction, estimated using a
bootstrapping method with 100 resamplings. **p < 0.01, ***p < 0.001, two-tailed fisher-exact test. d Enrichment of LM-related genes in DEG
subnetwork compared to all DEGs. Fraction of LM-related genes = 0.0384 (585/15,254) in expressed genes; 0.0626 (78/1247) in DEGs; 0.1958 (28/
143) in DEGs in the hippocampal interactome. p = 1.443E-5 between expressed genes and DEGs; p = 8.1167E-13 between expressed genes and
DEGs in the hippocampal interactome; p = 3.5114E-09 between all DEGs and DEGs in the hippocampal interactome. Error bars represent the
standard error of the fraction, estimated using a bootstrapping method with 100 resamplings. **p < 0.01, ***p < 0.001, two-tailed fisher-exact test.
e The top 10 KEGG pathways enriched with genes in the DEG subnetwork.
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extracted a subnetwork of ASD genes and their first co-
expressed PPI neighbors, which contains 212 nodes and
273 edges (Fig. 4a, Additional file 2: Table S8). Most of
the genes in the subnetwork of ASD did not show ex-
pression change, with 13.7% (29/212) of the genes up-
regulated and 3.8% (8/212) downregulated. Some of
these genes are well known to be involved in autism. For
example, mutations in Grin1 [50], Myh10 [51, 52],
Mapk1 [53], and Atp1a3 [54] were found in autism pa-
tients or mice. The expression change of these genes
may perturb the subnetwork of autism, leading to
autistic-like phenotypes of the knockout mice. To find
out the key nodes that might have control over the aut-
ism subnetwork, we calculated the node betweenness
centrality. The genes with the top 10 betweenness values
were Ywhaz, Grin1, Ctnnb1, Smarca4, Grin2b, Kcnma1,
Nf1, Esrrb, Plcb1, and Hoer1 (Fig. 4b). Among these
genes, only Grin1 is differentially expressed (upregu-
lated), suggesting it might play a key role in regulating
the signaling network underlying autistic-like behavior
of the knockout mice. Multiple studies have demon-
strated that the NMDARs are involved in regulating syn-
aptic plasticity [55] and the perturbations of NMDAR
functions are found in autistic brain [56].
We mapped the epilepsy (EP) candidate genes on the
mouse hippocampal interactome, and extracted a sub-
network of epilepsy candidate genes and their first co-
expressed PPI neighbors (Additional file 1: Figure S5),
which contains 113 nodes and 129 edges (Fig. 4c,
Additional file 2: Table S10). Most of the genes (86/113)
in the EP subnetwork did not show expression changes,
with 24 genes upregulated, including Grin1 (encoding
the NMDAR subunit 1) and six NMDAR interactors
(Dlg3, Dnm1, Psen1, Ppp3ca, Myh10, and Ptk2b), and
three genes (Dlg2, Dcx, and Flna) being downregulated.
The expression changes of these genes may perturb this
subnetwork, and thus may be related to the anti-epilepsy
phenotype. In order to identify the key genes that might
have more control over the EP subnetwork, we calcu-
lated the node betweenness centrality for each of the
nodes. Among the top 10 genes with the highest be-
tweenness values (Fig. 4d), the genes Grin1, Dnm1,
Actb, and Prnp are differentially expressed (upregu-
lated). The dysregulated Dnm1, Actb, and Prnp inter-
act with Grin1, suggesting that NMDAR system
(NMDARs and their regulators) might contribute to
the anti-epilepsy phenotype of this mouse model. We
hypothesize that the upregulation of NMDAR interac-
tors, such as Dlg3, Myh10, Ppp3a, Psen1, and Dnm1,
may contribute to the anti-epilepsy phenotype by
keeping the activity of NMDARs in control. This hy-
pothesis is supported by the fact that mutations in
Dlg3 [57], Psen1 [58], Dnm1 [59], and Ppp3ca [60]
have been found in epilepsy patients.
We mapped the 909 learning/memory (LM) related
genes (Additional file 2: Table S11) to the mouse hippo-
campal interactome and extracted a LM subnetwork
containing LM-related genes and their first co-expressed
PPI neighbors, which contains 194 nodes and 343 edges
(Fig. 4e, Additional file 2: Table S12). Most of the genes
(167/194) in the LM subnetwork did not show expres-
sion changes, with 22 genes upregulated and five genes
downregulated. Upregulated genes included Grin1 and
21 other genes (Fig. 4e), and downregulated genes in-
cluded five genes (Shank3, Shc3, Grin2c, Prkcb, Bcl2)
(Fig. 4e). Interestingly, in the LM subnetwork, Grin1 is
one of the top 10 genes that have the biggest values of
betweenness centrality (Fig. 4f), suggesting that they are
located at the center of the subnetwork. Grin1 may play
a key role in regulating the signaling network through
elevated expression. This result is consistent with previ-
ous findings that NMDARs are involved in synaptic plas-
ticity, long-term potential, learning, and memory [26].
Interestingly, in both the autism, the EP and LM subnet-
works, Grin1 had the biggest betweenness values among
DEGs (Fig. 4b, d, f), suggesting that NMDAR might play
a key role in regulating molecular pathways underlying
autism, anti-epilepsy, and enhanced learning/memory
phenotypes.
The three subnetworks for autism, epilepsy, and
learning/memory extracted from hippocampal interac-
tome network are involved in different aspects of re-
lated brain functions. We compared the three
subnetworks for their nodes (Fig. 4g) and found the
overlapping part of the subnetworks (Fig. 4h). The
overlapping part of these three subnetworks is a
dense module, containing Grin1 and Grin2b and their
interactors Prkce, Actin2, Mapk1, Bsn, Psen1, grin2a,
and Nsf. We carried out co-immunoprecipitation (Co-
IP) for the endogenous proteins GRIN1, GRIN2B, and
PSEN1 in mouse hippocampus. The GRIN1-GRIN2B
and GRIN1-PSEN1 interactions were confirmed by
Co-IP (Fig. 4i).
We speculated that the upregulated genes Grin1
and Prkce, Actin2, Mapk1, Psen1, and Nsf might con-
tribute to the comorbidity of autism with epilepsy
and abnormal learning and memory. We measured
the NMDA/AMPA conductance ratio recorded from
the soma in whole-cell voltage clamp mode in re-
sponse to stimulation of the Schaffer collateral path-
way. Because NMDA EPSC is hard to quantify, we
measured NMDA/AMPA conductance ratio as re-
ported in a previous study [38]. Consistent with this
study [38], we found an increased NMDA/AMPA
conductance ratio in KO mice (Fig. 4j), suggesting the
upregulated function of NMDARs compared with α-
amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid
receptor (AMPAR).
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Fig. 4 (See legend on next page.)
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Converged pathways in subnetworks for autism, epilepsy,
and learning/memory
To investigate potential shared pathways involved in
autistic-like behaviors, resistance to epilepsy, and en-
hanced learning/memory, we performed functional en-
richment analysis on the subnetworks for autism, epilepsy,
and learning/memory (Additional file 1: Figure S7, Add-
itional file 2: Table S16). The autism subnetwork is
enriched in 101 KEGG pathways, many of which are well
known involved in autism (Top 10 shown in Fig. 5a, full
list in Additional file 2: Table S13), such as long-term
potentiation [46], glutamatergic synapse [61], and Wnt
signaling pathway [62, 63]. This subnetwork is also
enriched in some pathways that are recently reported to
be involved in autism, such as the circadian entrainment
pathway [26, 64] and the thyroid hormone signaling path-
way [65] (Fig. 5a, Additional file 2: Table S13). Of these
101 pathways, 16 directly involve NMDAR genes. The epi-
lepsy subnetwork (EP subnetwork) is enriched in 44
KEGG pathways (top 10 shown in Fig. 5b and a full list in
Additional file 2: Table S14). Some of them are known to
be associated with epilepsy, such as long-term
Fig. 5 Enriched pathways with ASD, epilepsy, and LM subnetworks. a Top 10 enriched KEEG pathways with gene in ASD subnetwork. b Top 10
enriched KEGG pathways with genes in EP subnetwork. c Top 10 enriched KEGG pathways with genes in LM subnetwork. d The different and
common enriched pathways among the three subnetworks. The numbers are enriched pathways with the subnetworks. The numbers in brackets
are the pathways with NMDARs involved
(See figure on previous page.)
Fig. 4 Hippocampal protein interaction subnetworks for ASD, epilepsy and learning/memory. a ASD subnetwork. ASD candidate genes were
mapped onto the hippocampal interactome network to extract a subnetwork including ASD genes and first co-expressed PPI neighbors. b
Network betweenness centrality of top 10 genes in ASD subnetwork (X-axis, top 10 genes; Y-axis, betweenness centrality). c EP subnetwork.
Epilepsy candidate genes were mapped onto the hippocampal interactome network to extract a subnetwork including epilepsy genes and first
co-expressed PPI neighbors. d Network betweenness centrality of top 10 genes in EP subnetwork (X-axis, top 10 genes; Y-axis, betweenness
centrality). e LM subnetwork. Learning/memory (LM)-related genes were mapped onto the hippocampal interactome network to extract a
subnetwork including LM-related genes and first co-expressed PPI neighbors. f Network betweenness centrality of top 10 genes in LM
subnetwork (X-axis, top 10 genes; Y-axis, betweenness centrality). g Venn diagram of nodes in subnetworks. h The module of nodes shared by all
three subnetworks. i Co-immunoprecipitation was performed on hippocampal tissue lysates from 8-week mice to detect interactions between
endogenous protein pairs: GluN1 and GluN2B, GluN1 and PSEN1. Mouse IgG antibody was used as control in the pull down experiments. j
Sample traces (left) and summary bar graph (right) of measurements of the ratio of NMDA receptor-mediated versus AMPA receptor-mediated
synaptic responses recorded in slices; the NMDA/AMPA current ratio was determined by sequentially evaluating EPSC amplitudes at − 70 mV
(AMPA) and at + 40 mV (NMDA) holding potential; NMDA receptor-mediated responses were measured with the mean response between 110
and 160 ms post-stimulus. All data presented as mean ± SEM; n = 15 for WT cells from five mice and n = 14 for Gabra4−/− cells from five mice;
*p < 0.05, Student’s t test
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potentiation [66], synaptic vesicle cycle [67], cAMP signal-
ing pathway [68], and glutamatergic synapse [69]. Of these
44 pathways, 13 directly involve NMDARs. LM subnet-
work is enriched in 136 KEGG pathways (top 10 shown in
Fig. 5c and full list in Additional file 2: Table S15). Some
of them are known to be associated with learning and
memory, such as long-term potentiation [46] and Dopa-
minergic synapse [47] signaling pathways. Of these 136
pathways, 16 directly involve NMDARs.
We further compared the enriched pathways of these
three subnetworks and found 37 shared pathways (Fig.
5d), such as glutamatergic synapse, long-term potenti-
ation, Wnt signaling pathway. Of the 37 shared pathways,
13 contain NMDARs (Additional file 2: Table S16). This
observation is consistent with the converged molecular
network module of the three subnetworks (Fig. 4h).
Gene-pathway bipartite subnetworks for DEGs, autism,
epilepsy, and learning/memory
We performed signaling network analyses using data
from KEGG database (see Methods for details). The hip-
pocampal gene-pathway bipartite network was extracted
(Additional file 2: Table S17). Then we mapped DEGs,
ASD candidate genes, EP candidate genes, and LM-
related genes to the gene-pathway bipartite network and
extracted gene-pathway bipartite subnetworks (Add-
itional file 1: Figure S8A, C, E, G; Additional file 2: Table
S18–25). We extracted a common network module from
the DEG, ASD, EP, and LM gene-pathway bipartite sub-
networks (Additional file 1: Figure S8I, Additional file 2:
Table S26–27).
To validate the results obtained from PPI network
analyses, we compared the results from signaling net-
work analyses to those from PPI network analyses. The
involved pathways in the DEG, ASD, EP, and LM gene-
pathway bipartite subnetworks are largely overlapped
with the pathways identified from PPI subnetworks
(Additional file 1: Figure S8B, D, F, H, Additional file 2:
Table S28–31). Of the 123 enriched pathways in DEG-
pathway bipartite subnetwork, 86 (70.0%) of them are
also found to be enriched pathways in DEG-PPI subnet-
work (Additional file 1: Figure S8B, Additional file 2:
Table S28). Of the 121 enriched pathways in ASD gene-
pathway bipartite subnetwork, 82 (67.8%) of them are
also enriched pathways in ASD PPI subnetwork
(Additional file 1: Figure S8D, Additional file 2:
Table S29). Of the 48 enriched pathways in EP gene-
pathway bipartite subnetwork, 24 (50%) of them are
enriched pathways in EP PPI subnetwork (Additional file 1:
Figure S8F, Additional file 2: Table S30). Of the 183
enriched pathways in LM gene-pathway bipartite subnet-
work, 132 (72.1%) of them are also found in LM PPI sub-
network (Additional file 1: Figure S8H, Additional file 2:
Table S31). Consistent with the converged network module
of the PPI subnetworks for autism, epilepsy, and learning/
memory (Fig. 5h), the shared module of these three gene-
pathway bipartite subnetworks also involve NMDARs
(Grin1, Grin2a, and Grin2b) as hubs connecting to 16 path-
ways (Additional file 1: Figure S8 I and Additional file 2:
Table S31).
Discussion
The GABRA4 gene was reported to be associated with
autism in multiple ethnic groups [31, 32]. However, the
molecular mechanism remains unclear. Previous studies
on Gabra4 knockout mice demonstrated the involve-
ment of the Gabra4 subunit in synaptic plasticity and
spatial learning during puberty [35], and in contextual
fear memory [36], but did not report any autistic-like be-
haviors [35, 36], probably due to the ignorance of its as-
sociation with human autism. To investigate the
causality of GABRA4 in autism patients and underlying
molecular mechanism, we generated knockout mouse
model for Gabra4 and evaluated their autistic-like be-
haviors, learning/memory abilities, and susceptibility to
seizures, the three major phenotypic domains in autism
spectrum disorder.
The three phenotypic domains of human autism in-
clude (1) core clinical features, such as impaired social
interaction, and communication withdrawal, stereotyped
behaviors and restricted interests [1, 2]; (2) abnormal
intelligence [3, 4], such as severe intellectual disability
(IQ < 50), intellectual disability (IQ < 70) and high-
functioning autism (IQ > 70.); (3) relationship between
epilepsy and IQ of patients: 34% prevalence of epilepsy
in patients with IQ < 50, 27% in patients with IQ < 70,
9% in patients with IQ > 70, and 0.76% in normal popu-
lation [7, 8, 70]. The core clinical features are shared
phenotypes for all autistic patients, while the abnormal
intelligence and epilepsy only appear in ASD subtypes.
There are some relationships between autism and intel-
lectual disability, and between autism and epilepsy [8]:
lower IQ accompanies higher prevalence of epilepsy.
Therefore, we tested the phenotypes belong to these
three phenotypic domains in this potential animal model
for HF autism.
The Gabra4−/− mice displayed some autistic-like neuro-
behavioral dysfunction, specifically, impaired social inter-
action as manifested by a lack of preference for social
novelty (Fig. 1b), and repetitive behavior evident as in-
creased self-grooming (Fig. 1d). Our results suggest that
GABRA4 deficiency may contribute to the etiology of aut-
ism, confirming causality of GABRA4 variations identified
in the previous studies on ASD patients [32, 33]. Interest-
ingly, Gabra4 knockout mice showed enhanced spatial
learning and memory (Fig. 1f, g). The Gabra4 gene codes
for a subunit of the GABA receptor that mediates inhibi-
tory synaptic transmission and that contributes to tonic
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inhibition at extra-synaptic expression sites. Contrary to
our expectation, the Gabra4 knockout mice were resistant
to the convulsive drug pentylenetetrazol (PTZ), a GABA
antagonist, which causes excessive activation of the excita-
tory machinery (Fig. 1h). This result is consistent with
previous observation that increased expression of Gabra4
induces seizure [71]. The well-accepted hypothesis pro-
posed to explain that seizure is an increased ratio of exci-
tation to inhibition, which results in reduced seizure
threshold. These phenotypes of Gabra4−/− mice show HF-
autism-like features: impaired social interaction and re-
petitive behaviors, no intellectual disability (even better
than normal in spatial learning and memory) and attenu-
ated susceptibility to seizure.
Transcriptome profiling on hippocampi of the
Gabra4−/− mice revealed genome-scale homeostatic
regulation of gene expression, with 787 genes upregu-
lated and 460 genes down-regulated (Fig. 2a). The up-
regulated genes show significant enrichments for ASD
and epilepsy candidate genes and learning/memory-re-
lated genes (Fig. 2b–d), suggesting that a genome-wide
homeostatic regulation of gene expression change may
be involved molecular mechanism underlying the ob-
served autistic-like behaviors in the mouse model. These
upregulated genes are enriched for functions in neuronal
development, which are known to be related to autism
(Fig. 2e, f). Consistent with previous findings, the upreg-
ulated genes are also involved in ion transport (e.g.,
Gabra2, Grin1, Kcnc1) and synapse (e.g., Nlgn2, Syp).
Many lines of evidence have suggested that synaptic dys-
function is involved in the etiology of autism [72] and
intellectual disability [73]. The enrichment of human
ASD and epilepsy candidate genes and LM-related genes
in the hippocampal differentially expressed genes further
confirms the Gabra4−/− mouse as a potential animal
model for a subtype of autism at molecular level.
A total number of 15,254 genes are expressed in the
hippocampus. We mapped these genes onto the mouse
interactome (obtained from BioGRID) and extracted
mouse hippocampal interactome (Additional file 1: Fig-
ure S5). To illustrate the molecular mechanisms under-
lying the phenotypes of the mouse model, we extracted
four the DEG subnetwork from the hippocampal inter-
actome (Fig. 3a). The DEG subnetwork shows significant
additional enrichments with ASD candidate genes, epi-
lepsy candidate genes, and LM-related genes compared
to all DEGs (Fig. 3b–d), suggesting that these genes
function together and contribute to the etiology of this
mouse model. Looking into the DEG subnetwork, we
found that some well-known ASD candidate genes, such
as Kcnma1, Shank2, Cacna1a and Cacna1b, and epilepsy
candidate genes, such as Scn3a, Grin2a, Gabrg2, and
Grin2b, are hub genes in this subnetwork. These results
suggest that abnormal expression of these genes may
affect signaling pathways underlying the three pheno-
typic domains of high-functioning autism, including
ASD-like behaviors, enhanced learning/memory, and
anti-epilepsy phenotype.
Besides the core features of autism, autistic patients al-
ways show a spectrum of cognitive dysfunctions and
sometimes epilepsy/anti-epilepsy features. To further
search for converged pathways involved in autistic-like
behaviors, abnormal learning/memory and anti-epilepsy
phenotypes of Gabra4 knockout mice, we mapped aut-
ism candidate genes onto the hippocampal interactome
and extracted ASD subnetwork (Fig. 4a, b), EP subnet-
work (Fig. 4c, d), and LM subnetwork (Fig. 4e, f). The
ASD subnetwork has interconnected many signaling
pathways which are reported to be involved in autism,
such as long-term potential signaling [46], glutamatergic
synapses [61], and Wnt signaling [62, 63] (Fig. 5a,
Additional file 2: Table S13). The EP subnetwork is
enriched for pathways, such as glutamatergic [74] and
dopaminergic synapse [75] pathways, which are well
known to be involved in epilepsy (Fig. 5b, Additional file
2: Table S14). Among the upregulated genes, Grin1 has
the biggest betweenness values in all the subnetworks
(Fig. 4a–f), suggesting the central position of Grin1 in
these subnetworks. These subnetworks have 17 nodes in
common, most of which interconnect with each other to
form a converged network module (Fig. 4h), with Grin1
and Grin2b at the center position. The upregulation of
Grin1 and its five interactors in this converged network
module may play a key role in regulating the three sub-
networks underlying the three phenotypic domains.
Consistent with the upregulation of NMDAR system, we
found an increased NMDA/AMPA conductance ratio in
KO mice (Fig. 4j). These three subnetworks share 37
enriched pathways, most of which involve NMDAR sys-
tem (Fig. 5d). We also performed gene-pathway bipartite
network analyses using data from KEGG database and
extracted subnetworks for ASD candidate genes, EP can-
didate genes, and LM-related genes and the enriched
pathways in these three bipartite subnetworks are largely
overlapping with those in PPI subnetworks (Additional
file 1: Figure S8A-H). The shared network module of
these three gene-pathway bipartite subnetworks contains
NMDAR-involved pathways as hubs (Additional file 1:
Figure S8I), confirming that NMDAR system may play
central role in regulating the pathways involved in deter-
mining the three phenotypic domains.
Limitations
There are several limitations in this study. First, the phe-
notypes of the knockout mice may not accurately repre-
sent the phenotypes of autism. Three-chamber test was
used to evaluate the sociability and social novelty, but
the impairment of verbal communication in human
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autism, one of the core features of autism, was not able
to be measured. Second, the Morris water maze was
used to test the special learning and memory, but human
intelligence was much more complicated than spatial
learning and memory alone. Therefore, the results from
our study on this “high-functioning autism-like” mouse
model may not fully apply in the case of human autism.
Third, we identified distinct and shared pathways under
the three phenotypic domains of high functioning aut-
ism: autistic-like behaviors, enhanced learning/memory,
and anti-epilepsy phenotype. However, such analyses
were based on protein-protein interaction data and gene
expression profiling. Therefore, a more detailed molecu-
lar signal transduction processes are needed in order for
us to have a clear picture of the mechanism.
Conclusion
We have shown that Gabra4 knockout mice exhibit
autistic-like behaviors and attenuated PTZ-induced seiz-
ure and enhanced learning/memory. The transcriptome
sequencing on the hippocampus revealed a landscape of
dysregulated genes with significant enrichment of ASD
and epilepsy candidate genes. By the generation of hip-
pocampal interactome, we have constructed subnet-
works for autism candidate genes, epilepsy candidate
genes, and learning/memory-related genes. These three
subnetworks have a converged module with NMDAR
system at central position and also share some enriched
pathways involving NMDARs and their regulators, sug-
gesting that these converged NMDAR pathways might
be the commonly affected in autism spectrum disorder.
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Additional file 1: Figure S1. Genotyping of Gabra4-/- mice and
behavior tests. A Mutants were identified by Sanger sequencing. B
Gabra4-/- mice showed no significant preference for the both chambers
on the left and right (n = 16 for WT, and n = 8 for Gabra4-/-). No
significance, Student’s t test. C Gabra4-/- mice (n = 11) and wild type
mice (n = 11) traveled similar total distance during 30-minute open field
test. D During the first 5 minutes in open field test, Gabra4-/- mice spent
less time in the center zone compared to wild type mice. No significance,
n = 19 for WT, n = 11 for Gabra4-/-, Student’s t test. E Both WT and
Gabra4-/- buried similar number of marbles. No significance, n = 10 for
WT, n = 9 for Gabra4-/- mice, Student’s t test. F-G Gabra4-/- mice showed
similar percentage of freezing time during training (F) and test day (G) as
WT mice. No significance, n = 9 for WT, n = 7 for Gabra4-/-, Student’s t
test. H Gabra4-/- and WT displayed the similar velocity. No significance, n
= 13 for WT, n = 16 for Gabra4-/-, Student’s t test. All data presented as
mean ± SEM. Figure S2. Increased excitatory synapses. A The representative
pictures of spine density of the hippocampus from wild type mice and
Gabra4-/- mice. Brain tissues from mice 10 weeks old were used for Golgi-
Cox staining and dendritic spines were examined in Ix71 inverted
microscope with a 100× objective oil immersion lens (Olympus Life
Science). The number of spines per 30 μm of dendrite was compared
between genotypes. B Quantification of dendritic spine density in WT versus
Gabra4-/- neurons. Data are presented as scatter grams (with mean ± SEM
superimposed), each point corresponds to the mean spine density for a
single neuron. Gabra4-/- mice showed increased spine density (WT, n = 39
neurons from 3 animals, Gabra4-/-, n = 50 neurons from 4 animals, p =
0.0403, Student’s t test). C The representative electron micrograph shows
the postsynaptic densities of the hippocampus from wild type mice and
Gabra4-/- mice. Scale bar, 200 nm. D Cumulative frequency distribution of
PSD length in postsynaptic density of WT and Gabra4-/- mice, respectively.
No significant difference between WT and mutant mice (n = 58 for WT, and
n = 48 for Gabra4-/- mice, Student’s t test). E Cumulative frequency
distribution of PSD thickness in postsynaptic density of WT and Gabra4-/-
mice, respectively. No significant difference between WT and mutant mice
(n = 59 for WT, and n = 48 for Gabra4-/- mice, Student’s t test). Figure S3.
PCA analysis of RNAseq data, clustering of DEGs and expression level of
GABA receptors and glutamate receptors. A PCA analysis of RNAseq data
was performed on genes with more than 1 raw counts in at least 4 samples
using plotPCA DEseq2. B Heatmap of DEGs was plotted on log2-
transformed expression data using pheatmap1.0.10 package. C-E Expression
levels of GABA receptors (C) and glutamate receptors (D and E) were
represented by the FPKM values calculated from the RNAseq data. The
p Values were calculated using Student's t-test. F-H Real-time PCRs were
carried out on the differentially expressed GABA receptor Gabra2 (F) and
glutamate receptors Grin1 (G) and Grin2c (H). All data presented as mean ±
SEM; n = 7 for WT and n = 5 for Gabra4-/- mice; The p Values were
calculated using Student's t-test. Figure S4. Distinct functions between
upregulated and downregulated genes (DEGs). A Schizophrenia candidate
genes are enriched in Gabra4-/- differential expression genes. Error bars
represent the standard error of the fraction, estimated using bootstrapping
method with 100 resamplings. **p < 0.01, Fisher’s exact test. B The enriched
cellular components of GO terms with DEGs. The top 10 enriched terms
with up- and down-regulated genes. C The enriched molecular functions of
GO terms with DEGs. The top 10 enriched terms with up- and down-
regulated genes. Figure S5. Construction of hippocampal interactome
network and extraction of DEG subnetwork, ASD subnetwork, LM
subnetwork and EP subnetwork. The mouse hippocampal interactome,
which contained 4,202 nodes and 9,205 edges, was constructed by
integrating the hippocampal expressed genes and a protein interaction data
from BioGRID (Biological General Repository for Interaction Datasets). Four
subnetworks were extracted by mapping the “seeds” (DEGs, ASD candidate
genes, LM-related genes or EP candidate genes) on to the hippocampal
interactome network to include the interconnected “seeds” and their co-
expressed neighbors in the hippocampal interactome network. Figure S6.
Subnetworks extracted from randomized PPI networks compared to real
subnetworks. Mouse PPI interactome from BioGRID was randomized for
1,000 times by shuffling nodes and 4 sets of seeds (DEGs, ASD candidates,
EP candidates, LM candidates) were mapped onto the 1,000 randomized
networks to extract subnetworks as controls. The size distribution of each
control set of subnetworks was plotted in comparison with the size of each
real subnetwork. Blue lines indicate the mean sizes of the control
subnetworks, and red arrows indicate the sizes of the real subnetworks. A
Node counts distribution of DEG subnetworks extracted from randomized
networks. B Edge counts distribution of DEG subnetworks extracted from
randomized networks. C Node counts distribution of ASD subnetworks
extracted from randomized networks. D Edge counts distribution of ASD
subnetworks extracted from randomized networks. E Node counts
distribution of EP subnetworks extracted from randomized networks. F Edge
counts distribution of EP subnetworks extracted from randomized networks.
G Node counts distribution of LM subnetworks extracted from randomized
networks. H Edge counts distribution of LM subnetworks extracted from
randomized networks. Figure S7. Comparison of the enriched pathways
with ASD, epilepsy and LM subnetworks. The comparison of enriched KEGG
pathways with the three subnetworks. There are 37 enriched pathways
shared by three subnetworks. The enrichment analysis was performed using
DAVID bioinformatics tool with a p-value cutoff of 0.05 and FDR less than
0.05. ASD: autism; EP: epilepsy; LM: learning/memory. Figure S8. Gene-
pathway bipartite networks for DEGs, ASD candidates, EP candidates, LM-
related genes. A DEG-pathway bipartite subnetwork. DEGs were mapped
onto the hippocampal expressed gene-pathway bipartite network to extract
a subnetwork including DEGs and their involved pathways, and the
pathways significantly enriched with DEGs (p < 10-6) and containing at least
10 seed genes were kept. B Comparison of enriched pathways in DEGs PPI
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subnetwork and DEG-pathway bipartite subnetwork. C ASD gene-pathway
bipartite subnetwork. ASD candidate genes were mapped onto the
hippocampal expressed gene-pathway bipartite network to extract a
subnetwork including ASD candidate genes and their involved pathways,
and the pathways significantly enriched with ASD candidate genes (p <
10-6) and containing at least 10 seed genes were kept. D Comparison of
pathways enriched in ASD PPI subnetwork and ASD gene-pathway bipartite
subnetwork. E EP gene-pathway bipartite subnetwork. EP candidate genes
were mapped onto the hippocampal expressed gene-pathway bipartite
network to extract a subnetwork including EP candidate genes and their
involved pathways, and the pathways significantly enriched with EP
candidate genes (p < 10-6) and containing at least 10 seed genes were kept.
F Comparison of pathways involved in EP PPI subnetwork and EP gene-
pathway bipartite subnetwork. G LM gene-pathway bipartite subnetwork.
LM-related genes were mapped onto the hippocampal expressed gene-
pathway bipartite network to extract a subnetwork including LM-related
genes and their involved pathways, and the pathways significantly enriched
with LM-related genes (p < 10-6) and containing at least 10 seed genes were
kept. H Comparison of pathways involved in LM PPI subnetwork and LM
gene-pathway bipartite subnetwork. I The network module shared by all
three gene-pathway bipartite subnetworks. Fisher’s exact test was used for
calculating all the p values.
Additional file 2: Table S1. The 15,254 expressed genes. Table S2. The
gene list of hippocampal interactome. Table S3. The 9205 interactions
among the expressed genes. Table S4. The 1247 differentially expressed
genes. Table S5. The 787 upregulated genes. Table S6. The 460
downregulated genes. Table S7. The gene list of DEG subnetwork. Table
S8. The gene list of ASD subnetwork. Table S9. The list of 647 epilepsy
candidate genes. Table S10. The gene list of epilepsy subnetwork. Table
S11. The list of 909 learning/memory related genes. Table S12. The
gene list of learning/memory subnetwork. Table S13. The KEGG clusters
involved in ASD subnetwork. Table S14. The KEGG clusters involved in
epilepsy subnetwork. Table S15. The KEGG clusters involved in learning/
memory subnetwork. Table S16. The common KEGG clusters involved in
three subnetworks. Table S17. Hippocampal gene-pathway bipartite
network. Table S18. Hippocampal DEG gene-pathway bipartite network.
Table S19. Hippocampal ASD gene-pathway bipartite network. Table
S20. Hippocampal EP gene-pathway bipartite network. Table S21.
Hippocampal LM gene-pathway bipartite network. Table S22. Genes
involved in DEG gene-pathway bipartite network. Table S23. Genes
involved in ASD gene-pathway bipartite network. Table S24. Genes
involved in EP gene-pathway bipartite network. Table S25. Genes
involved in LM gene-pathway bipartite network. Table S26. Hippocampal
converged-pathway bipartite network module. Table S27. Genes
involved in converged gene-pathway bipartite network module. Table
S28. Comparison of enriched pathways in DEG-pathway bipartite
network and those enriched in DEGs PPI network. Table S29.
Comparison of enriched pathways in ASD gene-pathway bipartite
network and those enriched in ASD PPI network. Table S30. Comparison
of enriched pathways in EP gene-pathway bipartite network and those
enriched in EP PPI network. Table S31. Comparison of enriched
pathways in LM gene-pathway bipartite network and those enriched in
LM PPI network.
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